Renaud Maloberti - ENDRA Life Chief Commercial Officer
| NDRA Stock | USD 5.09 0.18 3.42% |
Executive
Mr. Renaud Bertrand Maloberti is Chief Commercial Officer of the company. Maloberti brings over 20 years of commercial medical imaging experience to ENDRA Life Sciences, including 12 years in ultrasound. Most recently, Maloberti served as the Chief Commercial Officer of Bionik Laboratories, a rehabilitation robotics company. Prior to Bionik, Maloberti served as Vice President and General Manager at FujiFilm SonoSite, where he led the development and commercialization of the world first highfrequency ultrasound, leading the division through doubledigit revenue growth for six years. Maloberti has also served as General Manager, Americas for BK Medical Systems, the ultrasound subsidiary of Analogic Corporationrationration. Earlier in his career, Maloberti worked at Draeger Medical Systems, a leader in patient monitoring and healthcare IT systems. Maloberti also spent 10 years in sales and marketing roles at GE Healthcare, a global leader in diagnostic imaging and ENDRA strategic partner. Maloberti holds an MBA in global marketing from Babson College, and a Bachelor Degree in International Finance from ESLSCA Business School in Paris, France. He is fluent in English in French. since 2019.
| Age | 55 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | 3600 Green Court, Ann Arbor, MI, United States, 48105-1570 |
| Phone | 734 335 0468 |
| Web | https://endrainc.com |
ENDRA Life Management Efficiency
The company has return on total asset (ROA) of (0.6094) % which means that it has lost $0.6094 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2013) %, meaning that it created substantial loss on money invested by shareholders. ENDRA Life's management efficiency ratios could be used to measure how well ENDRA Life manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -1.56. In addition to that, Return On Capital Employed is expected to decline to -1.89. At present, ENDRA Life's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 3.4 M, whereas Total Assets are forecasted to decline to about 6.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Austin Aerts | Sera Prognostics | 37 | |
| Josh Fischer | DarioHealth Corp | N/A | |
| Claudia Levi | DarioHealth Corp | N/A | |
| BS MB | Standard Biotools | 64 | |
| James MD | Biodesix | N/A | |
| Lisa MetznerRosas | Neuronetics | N/A | |
| Rick Grubbs | Neuronetics | N/A | |
| Dallas Coleman | bioAffinity Technologies Warran | N/A | |
| Rusty Page | Neuronetics | N/A | |
| Hao Liu | Burning Rock Biotech | 50 | |
| Mary Mooney | DarioHealth Corp | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Brian Harrigan | DarioHealth Corp | N/A | |
| William Bauta | bioAffinity Technologies Warran | N/A | |
| Victoria Gavrilenko | Intelligent Bio Solutions | 41 | |
| Jeffrey Black | Standard Biotools | 55 | |
| Cory Anderson | Neuronetics | N/A | |
| Mona Dean | DarioHealth Corp | N/A | |
| Xiaozhi Hu | Burning Rock Biotech | N/A | |
| Kieran OKane | Biodesix | 47 | |
| Shane Bowen | Standard Biotools | N/A | |
Management Performance
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.61 |
ENDRA Life Sciences Leadership Team
Elected by the shareholders, the ENDRA Life's board of directors comprises two types of representatives: ENDRA Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ENDRA. The board's role is to monitor ENDRA Life's management team and ensure that shareholders' interests are well served. ENDRA Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ENDRA Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Thornton, Chief Officer | ||
| Renaud Maloberti, Chief Commercial Officer | ||
| Ziad Rouag, Head Affairs | ||
| Alexander Tokman, Acting Chairman | ||
| Jonathan Behr, CoFounder | ||
| Francois Michelon, Chairman of the Board, CEO | ||
| Richard Jacroux, Chief Officer | ||
| Irina Pestrikova, Senior Secretary | ||
| Steve Freeman, Human Leader |
ENDRA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ENDRA Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.2 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | (1.87 M) | ||||
| Shares Outstanding | 518.28 K | ||||
| Shares Owned By Insiders | 0.28 % | ||||
| Shares Owned By Institutions | 0.49 % | ||||
| Number Of Shares Shorted | 841.05 K | ||||
| Price To Earning | (0.93) X | ||||
| Price To Book | 0.40 X | ||||
| EBITDA | (9.78 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ENDRA Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ENDRA Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Endra Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Endra Life Sciences Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in ENDRA Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ENDRA Life. If investors know ENDRA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ENDRA Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share -3 K | Return On Assets (0.61) | Return On Equity (1.20) |
The market value of ENDRA Life Sciences is measured differently than its book value, which is the value of ENDRA that is recorded on the company's balance sheet. Investors also form their own opinion of ENDRA Life's value that differs from its market value or its book value, called intrinsic value, which is ENDRA Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ENDRA Life's market value can be influenced by many factors that don't directly affect ENDRA Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ENDRA Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if ENDRA Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ENDRA Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.